Issues in biochemical applications to risk assessment: when can lymphocytes be used as surrogate markers?

Issues in biochemical applications to risk assessment: when can lymphocytes be used as surrogate markers?

During the course of this conference it has become clear that the application of in vitro, as well as in vivo, models for toxicity might be able to help us a great deal in our efforts to conduct more accurate species-to-species extrapolations of risk. However, the question remains: How do we monitor populations to determine if a particular biochemical pathway might have been perturbed or to det...

Issues in biochemical applications to risk assessment: can in vitro studies assist us in species extrapolation?

My topic today is, Can in vitro studies assist us in species extrapolation? And I'm going to narrow this topic a little bit simply by concentrating on human data, thinking that is the species that we're most interested in. I would like to redefine the question and ask, Can in vitro studies or in vivo-in vitro studies be used to assess human genotoxicity? I'd like to start with a quote from Dr. ...

Issues of biochemical applications to risk assessment: how should the MTD be selected for chronic bioassays?

a question that read, "How should the MTD be selected for chronic bioassays?" As a prelude, the response to the question warrants a brief review of the historical evolution of this issue. Table 1 is a summary of the historical chronology by which the dose selection process has evolved over the past 30 years. In the early to mid-1950s, the major emphasis was in the evaluation of chronic organ to...

Lymphocytes Can Be Identified by Characteristic Markers

Overweight can be used as a tool to guide case-finding for cardiovascular risk assessment.

BACKGROUND In general practice, it is too time-consuming to invite all patients for cardiovascular risk assessment. OBJECTIVE To examine how many patients with an indication for treatment with cardiovascular medication can be identified by ad hoc case-finding when all patients with overweight/obesity are invited for risk assessment. METHODS A cross-sectional analysis of the baseline measure...